GlassScriptPhysician profile
Jacob Sweidan
NPI 1265494835
$1,195.31
in general payments reported to CMS, 2019-2025
15 companies · $273 in 2025
The $273 reported for 2025 was more than what 87% of Neonatal-Perinatal Medicine providers received nationally (typical 2025 total: $77.90).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.02 · 2023: $384 · 2024: $520 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,177.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $280.19 | 2022-2025 | Bexsero, Nucala, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $219.56 | 2024 | |
| Merck Sharp & Dohme LLC | $172.13 | 2023-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi Pasteur INC. | $129.37 | 2023-2025 | |
| Cranial Technologies, INC | $126.65 | 2024-2025 | Doc Band |
| Abbvie INC. | $72.96 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.96 | 2024 | Cuvitru |
| Grifols USA, LLC | $27.91 | 2023 | Prolastin-C Liquid |
| Hologic Sales and Service, LLC | $23.80 | 2025 | Aptima |
| Astrazeneca Pharmaceuticals LP | $20.00 | 2024 | Fasenra |
| Janssen Pharmaceuticals, INC | $19.45 | 2023 | Xarelto |
| Philips North America LLC | $18.35 | 2023 | |
| Intuitive Surgical, INC. | $17.59 | 2024 | |
| Exact Sciences Corporation | $17.43 | 2025 | The Cologuard Plus Collection Kit |
| Cipher Pharmaceuticals US LLC | $15.96 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Sweidan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.